For women, especially those under 40, a diagnosis of breast cancer is difficult enough to hear. But when compounded with the fact that she might not be able to retain her fertility after undergoing chemotherapy, it can be doubly devastating.
Realizing this, researchers have begun medical treatments on younger females who have early stage breast cancer to suppress the women’s ovaries. Using triptorelin, physicians in an Italian study have successfully been able to help breast cancer victims stave off early menopause, a common side effect of chemotherapy. Patients in the study were able to potentially avoid permanently losing their fertility, enabling them to possibly have children naturally in the future.
The use of triptorelin to reduce the rate of early menopause in subjects by greater than 17 percent made waves throughout the international fertility treatment community, especially after the Italian study was made public earlier this week by the Journal of the American Medical Association.
Of course, it’s important to note that results haven’t been confirmed long-term and are only the tip of the iceberg. Cautions oncologist Lucia Del Mastro, the study’s leading author, in an article widely spread throughout the Internet:
“This strategy [of using triptorelin] increases the probability of ovarian function maintenance but it doesn’t assure the fertility.”
Still, it’s a happy prospect for women who have been given the devastating news that they have breast cancer and who want to have children later in life.